EUVIMEDEUVIMED entdecken
Crossref

Compliance with endocrine therapy among breast cancer survivors

Emma Marie Torpe, Tobias Berg, Maj-Britt Jensen, Bent Ejlertsen

Danish Medical Journal · 2024

DOI: 10.61409/a05240316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Danish Medical Journal, 2024. Verfasst von Emma Marie Torpe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Danish Breast Cancer Group, Department of Oncology, Copenhagen University Hospital - Rigshospitalet. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Hormonal, Cancer Survivors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION. Most postmenopausal women with early-stage oestrogen receptor-positive breast cancer are allocated to five years of endocrine therapy. This treatment is not without adverse effects, which may lead to treatment discontinuation. This study aimed to assess compliance with endocrine therapy among postmenopausal women with early-stage oestrogen receptor-positive breast cancer and examine its association with disease-free survival. METHODS. This study retrospectively identified a cohort of 360 postmenopausal women diagnosed in the period from 1 January 2015 to 31 December 2017 at Rigshospitalet, Copenhagen, Denmark, with early-stage oestrogen receptor-positive breast cancer in the clinical database of the Danish Breast Cancer Group. Kaplan-Meier was used to estimate compliance and disease-free survival. RESULTS. A total of 346 patients receiving endocrine therapy were included, 240 were compliant, and 106 were non-compliant. The median follow-up was 6.5 years (95% confidence interval (CI): 6.4-6.7 years). The compliance at 4.5 years was 68.8% (95% CI: 64.1-74.0%). Disease-free survival was significantly higher for the compliant group (adjusted HR = 2.29; 95% CI: 1.34-3.91). CONCLUSIONS. We found a low compliance at 4.5 years and most discontinuations were due to adverse effects. The study provides evidence that low compliance with endocrine therapy had a negative impact on disease-free survival. FUNDING. The study was funded by the Danish Cancer Society. TRIAL REGISTRATION. The study was approved by the research overview of the Capital of Denmark and the Center for Health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Agents, HormonalCancer SurvivorsHumansFemaleRetrospective StudiesMiddle AgedDenmarkAgedDisease-Free SurvivalPostmenopauseMedication AdherenceKaplan-Meier EstimateReceptors, EstrogenAromatase InhibitorsTamoxifen

Substanzen

Antineoplastic Agents, HormonalReceptors, EstrogenAromatase InhibitorsTamoxifen

Autor:innen und Institutionen

  • Danish Breast Cancer Group, Department of Oncology, Copenhagen University Hospital - Rigshospitalet.
  • Department of Oncology, Copenhagen University Hospital - Rigshospitalet.
  • Department of Clinical Medicine, University of Copenhagen, Denmark.

Zitieren

APA

Torpe, E. M., Berg, T., Jensen, M. B., & Ejlertsen, B. (2024). Compliance with endocrine therapy among breast cancer survivors. Danish Medical Journal. https://doi.org/10.61409/a05240316

Vancouver

Torpe EM, Berg T, Jensen MB, Ejlertsen B. Compliance with endocrine therapy among breast cancer survivors. Danish Medical Journal. 2024. doi:10.61409/a05240316

BibTeX
@article{Torpe2024,
  author = {Torpe, Emma Marie and Berg, Tobias and Jensen, Maj-Britt and Ejlertsen, Bent},
  title = {Compliance with endocrine therapy among breast cancer survivors},
  journal = {Danish Medical Journal},
  year = {2024},
  doi = {10.61409/a05240316}
}
Kostenlos starten →